By joining the drug to a dendrimer construct, very large increases in drug solubility have been achieved, which can enhance the “bioavailability” of the drug.
For example Docetaxel is a cancer drug well known for its poor aqueous solubility. When conjugated to a dendrimer construct a 20,000 fold increase in solublised Docetaxel is achieved.
The formulation of DEPTM docetaxel is also Polysorbate 80-free.
DEPTM docetaxel (vial on right) 20,000 x increase in water solubility